MonumenTAL-1: Proactive Management of Oral Toxicities
Following a review of oral adverse events, the expert panel discusses how to manage oral toxicities seen in patients with multiple myeloma who are treated with talquetamab.
This is a video synopsis/summary of a Between The Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.
Strategies to mitigate talquetamab-induced taste changes include topical dexamethasone rinses, tart candies as taste stimulants, saliva substitutes, dietary changes, nutrition consult for at-risk patients, prompt oral thrush treatment, and icing salivary glands given observed uptake. However, no interventions are definitively effective. Alternate talquetamab scheduling helps some patients, particularly reducing frequency to every 2 weeks initially or monthly dosing once response is attained. Some taste improvement follows talquetamab discontinuation with recurrence upon restarting. Compared with talquetamab, chimeric antigen receptor T-cell therapy targeting GPRC5D shows less taste distortion, indicating schedule dependency of bispecific antibody–mediated changes. Overall, tailoring administration frequency appears most impactful to managing oral adverse events, as monthly talquetamab enabled improved tolerance.
Video synopsis is AI generated and reviewed by Cancer Network® editorial staff.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
